KemPharm, Inc. (NASDAQ:KMPH) Files An 8-K Regulation FD Disclosure

KemPharm, Inc. (NASDAQ:KMPH) Files An 8-K Regulation FD Disclosure
Item 7.01          Regulation FD Disclosure.

Story continues below

On June 18, 2020, KemPharm, Inc., or the Company, issued a press release to announce that Travis C. Mickle, Ph.D., President and CEO of the Company, has issued a letter to shareholders in connection with the Company\’s 2020 Annual Meeting of Stockholders to be held on June 19, 2020. The letter provides an update on recent events and outlook for the remainder of 2020 and early 2021. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01, and the press release furnished as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01          Financial Statements and Exhibits.

 
 

KEMPHARM, INC Exhibit
EX-99.1 2 ex_190806.htm EXHIBIT 99.1 ex_165063.htm   Exhibit 99.1       KemPharm Issues Letter to Shareholders     Celebration,…
To view the full exhibit click here

About KemPharm, Inc. (NASDAQ:KMPH)

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company’s products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.

An ad to help with our costs